Introduction
============

Inflammation-related events such as edema, leukocyte recruitment, and pain are important for the protection of organisms, but excessive and persistent inflammation leads to tissue damage, chronic pain, and organ dysfunction. Therefore, knowledge of inflammation mechanisms is essential to treat inflammatory diseases and to promote host protection and homeostasis ([@B01]).

Oxidative stress is an important component of pain and inflammation. Similarly, antioxidants such as the flavonoid, quercetin, inhibit overt pain-like behavior, carrageenan-induced mechanical hyperalgesia, and paw edema by diminishing interleukin-1β production and reducing glutathione (GSH) depletion ([@B02]). Quercetin also inhibits leukocyte recruitment ([@B03]) and acetic acid-induced colitis in mice ([@B04]). This is a consistent effect observed with antioxidants ([@B05],[@B06]). Quercetin is considered to be a standard antioxidant flavonoid, because it presents all the structural groups related to antioxidant activity possessed by this class of molecules ([@B02]-[@B04]).

The role of reactive oxygen species (ROS) in pain and inflammation has been investigated *in vivo*. For instance, the superoxide dismutase (SOD) mimetics, M40403 and TEMPOL, inhibit carrageenan-induced thermal hyperalgesia, paw edema, and cytokine production by preventing the superoxide-induced nitration of SOD ([@B07],[@B08]). Similarly, SOD inhibition by diethyldithiocarbamic acid increases carrageenan-induced paw edema and thermal hyperalgesia ([@B08]). The generation of peroxynitrite by the co-administration of pyrogallol (superoxide anion generator) and of a nitric oxide donor (SNAP) also induces thermal hyperalgesia and paw edema ([@B08]).

The main inflammatory source of superoxide anion is the complex of phagocytic NADPH oxidase enzymes. Production of superoxide anion and its derivatives is related to opioid tolerance, chemotherapy-induced pain, neuropathic pain, neurogenic pain, and inflammatory pain ([@B09]).

Despite current evidence regarding the crucial role of superoxide in pain and inflammation, to our knowledge, there are limited experimental approaches for studying the induction of pain and inflammation directly by superoxide anion. There is evidence that potassium superoxide (KO~2~), a superoxide anion donor, induces thermal hyperalgesia in the Hargreaves method at 20 min ([@B07]) and 60 min ([@B10]) after its injection into the paw. However, to further support the use of KO~2~ for investigating a wide range of superoxide anion-induced inflammatory and pain responses, it remains to be determined whether KO~2~ induces additional nociceptive behaviors such as mechanical hyperalgesia and overt pain-like behaviors as well as inflammatory responses such as edema and leukocyte recruitment. In this context, we investigated KO~2~ as a trigger for pain and inflammation in mice and the susceptibility of these responses to the analgesic opioid, morphine, the antioxidant flavonoid, quercetin, and the cyclooxygenase-2 (COX-2) selective inhibitor, celecoxib.

Material and Methods
====================

Animals
-------

Male Swiss mice (25±5 g) from Universidade Estadual de Londrina were housed in standard plastic cages with free access to food and water, with a 12:12-h light/dark cycle, at 21°C. Care and handling procedures for the animals were in accordance with the International Association for the Study of Pain (IASP) guidelines and with the approval of the Ethics Committee of the Universidade Estadual de Londrina (process \#71.2012.68).

Drugs and reagents
------------------

KO~2~ (96.5%) was purchased from Alfa Aesar (USA). Quercetin at 95% purity was purchased from Acros (USA). Morphine, naloxone, hexadecyl trimethyl ammonium bromide, *o*-dianisidine dihydrochloride, GSH, EDTA sodium salt, ferric chloride hexahydrate, 2,4,6-tripyridyl-s-triazine, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonate (ABTS), and 6-hydroxy-2,5,7,8-tetramethylchroman-2-11 carboxylic (Trolox) were purchased from Sigma (USA).

Experimental protocols
----------------------

The parameters evaluated were mechanical hyperalgesia; thermal hyperalgesia; paw edema; paw flinches; paw licking; writhing response; total counts of leukocytes, mononuclear cells, and neutrophils; superoxide anion production; pharmacological susceptibility to morphine, quercetin, and celecoxib; oxidative stress methods (ferric-reducing ability potential \[FRAP\], ABTS, and GSH assays); and quantitative polymerase chain reaction (qPCR) for COX-2 mRNA expression. For mechanical hyperalgesia, thermal hyperalgesia, and paw edema, KO~2~ was administered by the intraplantar (*ipl*) route at doses of 3-100 μg/paw in a final volume of 25 µL sterile saline, followed by evaluation after 0.5-7 h. Paw flinches and time spent licking the paw were determined between 0 and 30 min after *ipl* injection of KO~2~ (1-30 μg/paw), and the total number of writhings was determined between 0 and 20 min after intraperitoneal (*ip*) injection of KO~2~ (30-1000 μg/cavity, in a final volume of 100 µL of sterile saline). Total counts of leukocytes, mononuclear cells, and neutrophils were evaluated 6 h after *ip* injection of KO~2~ (10-100 µg/cavity). Superoxide anion levels in KO~2~ saline solution were determined by reduction of nitrobluetetrazolium (NBT) *in vitro*.

The pharmacological susceptibility of KO~2~-induced nociception was determined using the opioid morphine, the antioxidant quercetin, and the COX-2 selective inhibitor celecoxib, as follows. Morphine: mice were treated with morphine (2-12 μg/paw, *ipl*, 20 µL, 30 min before measurement) and the opioid receptor antagonist naloxone (30 μg/paw, *ipl*, 1 h before morphine) or its vehicle. Quercetin: mice were treated with quercetin (10-100 mg/kg, *ip*) 30 min before KO~2~ injection (30 μg/paw, *ipl*). Total counts of leukocytes, mononuclear cells, and neutrophils (6 h after stimulus injection), and antioxidant status (FRAP, ABTS, and GSH assays, 3 h after stimulus) were evaluated in animals pretreated with quercetin (100 mg/kg, *ip*), 30 min before *ip* or *ipl* injection of KO~2~ (30 µg/cavity), respectively. Celecoxib: mice were treated with celecoxib (30 mg/kg, *ip*) 1 h before KO~2~ injection (30 μg/paw, *ipl* or *ip*, and 1 mg/mice), and the parameters evaluated were mechanical hyperalgesia, thermal hyperalgesia, paw flinches, paw licking, and the writhing response. Whether KO~2~ injection induced time-dependent (0.5-7 h) COX-2 mRNA expression by qPCR was also determined. Results are reported as means±SE of measurements of 6 mice/group per experiment, and are representative of two separate experiments. It is noteworthy that different investigators prepared the solutions, administered them, and performed the testing procedures.

Electronic pressure meter test
------------------------------

Mechanical hyperalgesia was assessed as previously reported ([@B11]). In a quiet room, mice were placed in acrylic cages (12×10×17 cm) with wire grid floors, 30 min before testing. The test consisted of evoking a hind paw reflex with a hand-held force transducer (electronic anesthesiometer; Insight Equipamentos, Brazil) adapted with a 0.5 mm^2^ polypropylene tip. The investigator was trained to apply the tip perpendicularly to the central area of the hind paw with a gradual increase in pressure. The end point was characterized by the removal of the paw followed by clear flinching movements, and the intensity of pressure was recorded automatically. The animals were tested before (basal) and after treatment and stimuli, and the value for each interval was an average of 3 measurements. The results are reported as the change (Δ) in withdrawal threshold (in g), calculated by subtracting the basal mean measurements from the mean measurements obtained at 0.5, 1, 3, 5, or 7 h after *ipl* injection of KO~2~ (3-100 µg/paw). The dose of KO~2~ of 30 µg/paw was selected for pharmacological testing.

Hot plate test
--------------

Mice were placed in a 10 cm wide glass cylinder on a hot plate (EFF 361, Insight Equipamentos) maintained at 55°C. Two control latencies at least 10 min apart were determined for each mouse. The normal latency (reaction time) was 12-20 s. The latency was also evaluated 0.5, 1, 3, 5, and 7 h after test compound administration. The reaction time was scored when the animal jumped or licked its paws. A maximum latency (cutoff) was set at 30 s to avoid tissue damage ([@B12]). A dose-response curve was performed using KO~2~ at doses of 3-100 µg/paw, and 30 µg/paw was selected for pharmacological testing.

Writhing response tests
-----------------------

Each mouse was placed in a large glass cylinder and the intensity of nociceptive behavior was quantified by counting the total number of writhings (contraction of the abdominal muscle together with a stretching of hind limbs) occurring between 0 and 20 min after *ip* injection of KO~2~. The intensity of nociceptive behavior was expressed as the cumulative number of writhings over 20 min. A dose-response curve was performed using KO~2~ at doses of 30-1000 µg/cavity (*ip*), and the dose of 1000 µg/mouse was selected for pharmacological testing.

Paw flinches and time spent licking test
----------------------------------------

The number of paw flinches and time spent licking the stimulated paw were determined between 0 and 30 min after *ipl* injection of KO~2~. Results are reported as the cumulative number of paw flinches and time spent licking the paw over 30 min. A dose-response curve was performed using KO~2~ at doses of 1-30 µg/paw, and 30 µg/paw was selected for pharmacological testing.

Paw edema
---------

Paw edema was measured using an analog caliper (Digmatic Caliper, Mitutoyo Corporation, Japan). Values of paw edema are reported as the difference between the paw thickness measured before (basal) and after induction of paw inflammation in millimeters. A dose-response curve was performed using KO~2~ at doses of 3-100 µg/paw, and 30 µg/paw was selected for pharmacological testing.

Myeloperoxidase (MPO) activity
------------------------------

The MPO kinetic-colorimetric assay was performed as described elsewhere ([@B11]) to verify leukocyte migration to the subcutaneous plantar tissue of the mouse hind paw. Seven hours after KO~2~ injection, the hind paw tissue of mice was collected and homogenized using Tissue-Tearor (Biospec, USA), centrifuged at 16,100 *g* for 4 min, and the resulting supernatant was assayed spectrophotometrically for MPO activity determination at 450 nm (Multi Scan Go Thermo Scientific, USA). The MPO activity of the samples was compared to a standard curve of neutrophils, and the results are reported as MPO activity (number of neutrophils×10^3^/mg of tissue). A dose-response curve was performed using KO~2~ at doses of 3-100 µg/paw, and 30 µg/paw was selected for pharmacological testing.

Leukocyte recruitment to the peritoneal cavity
----------------------------------------------

Peritoneal cavities were washed with 1 mL of phosphate-buffered saline (PBS) containing EDTA (37.2 mg/100 mL saline). Total leukocyte counts were performed in a Neubauer chamber after dilution in Turk\'s solution (2% acetic acid, v/v), and differential cell counts were performed using the Fast Panoptic Kit for histological analysis (Laborclin, Brazil). Results are reported as number of cells per cavity (×10^6^). Leukocyte recruitment was determined 6 h after KO~2~ injection. Total and differential cell counts were both performed under a light microscope (400× magnification, Olympus Optical Co., Germany) ([@B12]). A dose-response curve was calculated using KO~2~ at doses of 10-100 µg/paw, and 30 µg/paw was selected for pharmacological testing.

FRAP and ABTS assays
--------------------

Paw skin samples were collected and immediately homogenized with 500 μL of 1.15% KCl, and centrifuged (10 min×200 *g*×4°C). The ability of a sample to resist oxidative damage was determined using FRAP and ABTS assays ([@B13]). For the FRAP assay, 50 μL of supernatant was mixed with 150 μL of deionized water and 1.5 mL of freshly prepared FRAP reagent. The reaction mixture was incubated at 37°C for 30 min and absorbance measured at 595 nm. For the ABTS assay, the ABTS solution was diluted with PBS at pH 7.4 at an absorbance of 0.80 at 730 nm. Then 1.0 mL of diluted ABTS solution was mixed with 20 μL of supernatant. After 6 min, the absorbance was measured at 730 nm. The results were equated against a Trolox standard curve (1.5-30 μmol/L, final concentrations). The results are reported as Trolox equivalents per milligram of tissue weight in both assays.

GSH measurement
---------------

Paw skin sample was collected and maintained at -80°C for at least 48 h, then the sample was homogenized with 200 µL of 0.02 M EDTA; the homogenate was mixed with 25 µL of 50% trichloroacetic acid and homogenized three times for 15 min. The mixture was then centrifuged (15 min×1500 *g*×4°C) and the supernatant added to 200 µL of 0.2 M Tris buffer, pH 8.2, and 10 µL of 0.01 M DTNB. After 5 min, absorbance was measured at 412 nm against a blank reagent with no supernatant. A standard curve was calculated using standard GSH, and the results are reported as GSH per milligram protein ([@B14]). For protein determination, 60 µL of supernatant were mixed with 60 µL of freshly prepared copper reagent. After 10 min, 180 µL of Folin solution was added. The resulting solution was incubated at 50°C for 10 min, the absorbance was measured at 660 nm, and the results were equated to a standard curve of bovine serum albumin.

*In vitro* superoxide anion production assay
--------------------------------------------

An NBT reduction assay was carried out to evaluate the ability of KO~2~ to release superoxide anion at varied time points after its dilution in saline (30 µg, 25 µL). An equimolar solution of KOH diluted in saline was used as control. KO~2~ or KOH solutions were mixed with 100 µL of NBT reagent (1 mg/mL) at the indicated time points after dissolution. After 15 min of incubation at room temperature, the supernatants were carefully removed. The formazan precipitates were solubilized by addition of 120 µL of KOH (2 M) and 120 µL of DMSO, and absorbance was read at 600 nm ([@B15]).

qPCR
----

Paw skin samples were homogenized in TRIzol reagent (Life Technologies, USA), and total RNA was isolated according to the manufacturer\'s instructions. RNA purity was confirmed by the 260/280 ratio. RT-PCR and qPCR were performed using GoTaq 2-Step RT-qPCR System (Promega, USA) following the manufacturer\'s instructions. Complementary DNA was reversely transcribed from 2 mg of total RNA, and qPCR was performed for 50 cycles on a LightCycler Nano Instrument (Roche, Switzerland). Primer sequences were as follows: *Cox-2*, forward: 5′-GTGGAAAAACCTCGTCCAGA-3′, reverse: 5′-GCTCGGCTTCCAGTATTGAG-3′; and *Gapdh*, forward: 5′-CATACCAGGAAATGAGCTTG-3′, reverse: 5′-ATGACATCAAGAAGGTGGTG-3′.

Statistical analysis
--------------------

Results are reported as means±SE of measurements made on 6 mice/group per experiment and are representative of 2 separate experiments. Two-way analysis of variance (ANOVA) was used to compare the groups and doses at all times (curves). The analyzed factors were treatment, time, and time *vs* treatment interaction. When there was a significant time *vs* treatment interaction, one-way ANOVA followed by Tukey\'s *t*-test was performed for each time. On the other hand, when the nociceptive responses were presented as total values at the indicated time period, the differences between responses were evaluated by one-way ANOVA followed by Tukey\'s *t*-test. Statistical differences were considered to be significant at P\<0.05.

Results
=======

Superoxide anion donor KO~2~ induced mechanical hyperalgesia, thermal hyperalgesia, paw edema, and MPO activity
---------------------------------------------------------------------------------------------------------------

KO~2~ was administered *ipl* at doses of 3-100 μg/paw in a final volume of 25 μL of sterile saline. Mechanical hyperalgesia ([Figure 1A](#f01){ref-type="fig"}), thermal hyperalgesia ([Figure 1B](#f01){ref-type="fig"}), and paw edema ([Figure 1C](#f01){ref-type="fig"}) were evaluated 0.5-7 h after stimulus. All doses of KO~2~ induced statistically significant mechanical hyperalgesia compared to the control group (saline) at all time points, except the dose of 100 μg/paw ([Figure 1A](#f01){ref-type="fig"}). KO~2~ at 30 μg/paw induced statistically significant mechanical hyperalgesia compared to the other doses ([Figure 1A](#f01){ref-type="fig"}). KO~2~ induced mechanical hyperalgesia in a bell-shaped curve, achieving the maximal effect with 30 µg/paw and almost no mechanical hyperalgesia with 100 µg/paw. Regarding thermal hyperalgesia, doses of 3, 10, and 100 μg/paw of KO~2~ showed similar thresholds ([Figure 1B](#f01){ref-type="fig"}). Only the dose of 30 μg/paw induced a statistically significant reduction in thermal threshold when compared to the control group at all evaluated times ([Figure 1B](#f01){ref-type="fig"}). KO~2~ induced a dose-dependent increase in paw edema. KO~2~ did not induce paw edema at 3 μg/paw, the dose of 10 μg/paw induced paw edema at 0.5 and 1 h, and doses of 30 and 100 μg/paw induced paw edema at all time points ([Figure 1C](#f01){ref-type="fig"}). Only the dose of 30 μg/paw of KO~2~ induced a significant increase in MPO activity ([Figure 1D](#f01){ref-type="fig"}).

![Intraplantar (*ipl*) injection of KO~2~ induced hyperalgesia, edema, and neutrophil recruitment. Mice received KO~2~ (3-100 µg, 25 µL, *ipl*) or saline injection. The intensity of mechanical hyperalgesia (*A*), thermal hyperalgesia (*B*), and the paw edema (*C*) were measured 0.5-7 h after stimulus, and myeloperoxidase (MPO) activity at 7 h. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* 3 µg; \*\*P\<0.05 *vs* 10 µg; ^\#\#^P\<0.05 *vs* 30 µg (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf001){#f01}

Superoxide anion induced dose-dependent pain-like behavior
----------------------------------------------------------

KO~2~ was administered at doses of 1-30 μg/paw, and the number of flinches and the time spent licking the paw were quantified ([Figure 2, A and B](#f02){ref-type="fig"}). KO~2~ induced a dose-dependent increase in the number of paw flinches and time spent licking the paw. Only the dose of 30 μg/paw induced statistically significant nociceptive responses compared to the vehicle control group. The writhing response was induced only by a dose of 1000 µg/cavity of KO~2~ ([Figure 2C](#f02){ref-type="fig"}).

![KO~2~ induced overt pain-like behavior. The number of paw flinches (*A*), and the time spent licking the paw (*B*) were evaluated during 30 min after KO~2~ (1-100 µg, *ipl*) or saline injection. The writhing score was evaluated 20 min after KO~2~ (30-1000 µg, *ip*) or saline injection. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* 1 µg; \*\*P\<0.05 *vs* 300 µg (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf002){#f02}

Superoxide anion donor induced leukocyte recruitment
----------------------------------------------------

KO~2~ (10-100 μg/cavity) was injected *ip* and peritoneal exudates were collected after 6 h, which is a standard time point for acute leukocyte recruitment to the peritoneal cavity ([Figure 3A](#f03){ref-type="fig"}) ([@B16]). All doses induced significant increases in total leukocyte counts in a bell-shaped curve, with significant differences with the dose of 30 µg compared to 10 and 100 µg of KO~2~. A bell-shaped curve also resulted with counts for total mononuclear cells ([Figure 3B](#f03){ref-type="fig"}) and neutrophils ([Figure 3C](#f03){ref-type="fig"}). Again, the maximal effect was observed with the dose of 30 µg of KO~2~, which was selected for the leukocyte recruitment experiments in this study.

![KO~2~ induced leukocyte recruitment to the peritoneal cavity. The peritoneal cells were harvested 6 h after KO~2~ (10-100 µg, *ip*) or saline injection. Total (*A*) and differential (*B* and *C*) cell counts were determined. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* 10 µg; \*\*P\<0.05 *vs* 30 µg (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf003){#f03}

KO~2~ in saline presented time-dependent decay of superoxide anion levels
-------------------------------------------------------------------------

An important point to be determined was whether KO~2~ saline solution would present detectable superoxide anion, which was tested with KO~2~ solution at 30 µg/25 µL, a concentration selected on the basis of the results of [Figures 1](#f01){ref-type="fig"}-[](#f02){ref-type="fig"} [3](#f03){ref-type="fig"}. Saline solution did not reduce NBT, indicating that there was no detectable superoxide anion ([Figure 4](#f04){ref-type="fig"}). KO~2~ saline solution presented significant NBT reduction activity, indicating detectable superoxide anion levels at 1 and 5 min after solution preparation. Ten minutes after KO~2~ saline solution preparation, all NBT reducing activity vanished, indicating that no superoxide anions were present. A KOH saline solution at an equimolar concentration of the KO~2~ solution was tested as control. The KOH saline solution did not present detectable superoxide anion levels ([Figure 4](#f04){ref-type="fig"}). These results demonstrated that KO~2~ saline solution injected up to 5 min after its preparation presents significant amounts of superoxide anion, while the procedure for its injection into one group of mice takes approximately 3 min. Therefore, these data confirmed the successful administration of superoxide anion.

![KO~2~ dissolution in saline produced superoxide anion. KO~2~ (30 µg, 25 µL of saline) or KOH (equimolar concentration to KO~2~, 25 µL of saline) solutions were prepared and mixed with 100 µL of nitrobluetetrazolium (NBT) reagent at the indicated time points. Data are reported as means±SE. \*P\<0.05 *vs* saline control and KOH solution (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf004){#f04}

KO~2~-induced hyperalgesia and pain-like behavior were inhibited by morphine treatment
--------------------------------------------------------------------------------------

Mice received 30 μg/paw of KO~2~ and after 2 h were treated with morphine (opioid, 2-12 µg/paw) and, after an additional 1 h, mechanical ([Figure 5A](#f05){ref-type="fig"}) and thermal ([Figure 5B](#f05){ref-type="fig"}) hyperalgesia were evaluated. The dose of 2 µg morphine did not alter KO~2~-induced mechanical hyperalgesia, while 6 µg morphine reduced mechanical hyperalgesia compared to the control group, and 12 µg morphine reduced mechanical hyperalgesia compared to all lower doses ([Figure 5A](#f05){ref-type="fig"}). Morphine was also effective in reducing KO~2~-induced thermal hyperalgesia at a dose of 12 µg ([Figure 5B](#f05){ref-type="fig"}). Naloxone (1 mg/kg, *ip*, 30 min before morphine treatment) prevented the analgesic effect of morphine over KO~2~-induced mechanical ([Figure 5A](#f05){ref-type="fig"}) and thermal ([Figure 5B](#f05){ref-type="fig"}) hyperalgesia. Morphine at a dose of 12 µg/paw (cotreatment) also inhibited KO~2~-induced paw flinching ([Figure 5C](#f05){ref-type="fig"}) and licking ([Figure 5D](#f05){ref-type="fig"}) behaviors, and, again, naloxone treatment prevented the analgesic effect of morphine.

![Morphine inhibited KO~2~-induced hyperalgesia and overt pain-like behavior in a naloxone-sensitive manner. Mice were post-treated (*A* and *B*) with morphine (2-12 µg, *ipl*) or vehicle (saline) 45 min before the measurements. The nociceptive thresholds to mechanical (*A*) and thermal (*B*) stimuli were measured 3 h after KO~2~ (30 µg/paw) injection. In another set of experiments, mice were pre-treated (*C* and *D*) with morphine (12 µg, *ipl*) or vehicle (saline) 45 min before KO~2~ (30 µg/paw) or saline injection. The number of paw flinches (*C*), and the time spent licking the paw (*D*) were measured during 30 min. Treatment with naloxone is indicated as NLX (1 mg/kg, *ip*, 30 min before morphine injection). Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* KO~2~ control (black bars); \*\*P\<0.05 *vs* 6 µg morphine; ^\#\#^P\<0.05 *vs* 12 µg morphine (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf005){#f05}

The standard antioxidant flavonoid, quercetin, inhibited KO~2~-induced mechanical hyperalgesia, thermal hyperalgesia, and edema
-------------------------------------------------------------------------------------------------------------------------------

Mice were treated with quercetin (10-100 mg/kg, *ip*) 1 h before *ipl* injection of KO~2~ ([Figure 6](#f06){ref-type="fig"}). Quercetin inhibited KO~2~-induced mechanical hyperalgesia ([Figure 6A](#f06){ref-type="fig"}), thermal hyperalgesia ([Figure 6B](#f06){ref-type="fig"}), and paw edema ([Figure 6C](#f06){ref-type="fig"}) in a dose-dependent manner. Thus, the dose of 100 mg/kg quercetin was selected for the experiments presented in [Figures 7](#f07){ref-type="fig"}-[](#f08){ref-type="fig"} [9](#f09){ref-type="fig"}.

![Quercetin inhibited the KO~2~-induced mechanical hyperalgesia (*A*), thermal hyperalgesia (*B*), and edema (*C*) in a dose-dependent manner. Mice were treated with quercetin (10-100 mg/kg, *ip*) or vehicle (20% tween 80 in saline, 150 µL, *ip*) 1 h before KO~2~ (30 µg/paw) or saline injection. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* KO~2~ control; \*\*P\<0.05 *vs* 10 mg/kg; ^\#\#^P\<0.05 *vs* 30 mg/kg (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf006){#f06}

![Quercetin inhibited the KO~2~-induced overt pain-like behaviors. Mice were treated with quercetin (100 mg/kg, *ip*) or vehicle 1 h before stimuli. The number of paw flinches (*A*), and the time spent licking the paw (*B*) were quantified during 30 min after KO~2~ (30 µg/paw) injection. The writhing score (*C*) was quantified during 20 min after KO~2~ (1 mg, *ip*) injection. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* KO~2~ control (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf007){#f07}

![Quercetin inhibited the KO~2~-induced leukocyte recruitment. Mice were treated with quercetin (100 mg/kg, *ip*) or vehicle 1 h before KO~2~ (30 µg, *ip*) injection. The total number of leukocytes (*A*), mononuclear cells (*B*), and neutrophils (*C*) were determined 6 h after stimulus. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* KO~2~ control (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf008){#f08}

![Quercetin inhibited KO~2~-induced oxidative stress. Mice were treated with quercetin (100 mg/kg, *ip*) or vehicle 1 h before KO~2~ (30 μg/paw) injection. The antioxidant capacity was measured by ABTS (*A*), FRAP (*B*), and GSH (*C*) assays, 3 h after stimulus injection. ABTS: free-radical scavenging ability; FRAP: ferric-reducing ability potential; GSH: glutathione. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* KO~2~ control (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf009){#f09}

Quercetin inhibited KO~2~-induced overt pain-like behavior, leukocyte recruitment to the peritoneal cavity, and oxidative stress
--------------------------------------------------------------------------------------------------------------------------------

Quercetin inhibited KO~2~-induced overt pain-like behaviors of paw flinching ([Figure 7A](#f07){ref-type="fig"}), paw licking ([Figure 7B](#f07){ref-type="fig"}), and abdominal writhing ([Figure 7C](#f07){ref-type="fig"}). Quercetin also inhibited KO~2~-induced recruitment of total leukocytes ([Figure 8A](#f08){ref-type="fig"}), mononuclear cells ([Figure 8B](#f08){ref-type="fig"}), and neutrophils ([Figure 8C](#f08){ref-type="fig"}) to the peritoneal cavity of the mice. The *ipl* injection of KO~2~ induced diminished ABTS ([Figure 9A](#f09){ref-type="fig"}), FRAP ([Figure 9B](#f09){ref-type="fig"}), and GSH levels ([Figure 9C](#f09){ref-type="fig"}) in plantar skin samples. Quercetin inhibited a KO~2~-induced decrease in ABTS ([Figure 9A](#f09){ref-type="fig"}), as well as FRAP ([Figure 9B](#f09){ref-type="fig"}) and GSH levels.

The COX-2 selective inhibitor, celecoxib, inhibited KO~2~-induced nociception and COX-2 mRNA expression
-------------------------------------------------------------------------------------------------------

Mice were treated with celecoxib (30 mg/kg, *ip*) ([@B17]) 1 h before *ipl* (30 µg/paw) or *ip* (1 mg/mice) injection of KO~2~ ([Figure 10](#f10){ref-type="fig"}). Celecoxib inhibited KO~2~-induced mechanical hyperalgesia ([Figure 10A](#f10){ref-type="fig"}), thermal hyperalgesia ([Figure 10B](#f10){ref-type="fig"}), paw flinching ([Figure 10C](#f10){ref-type="fig"}), paw licking ([Figure 10D](#f10){ref-type="fig"}), abdominal writhing ([Figure 10E](#f10){ref-type="fig"}), and COX-2 mRNA expression in paw skin samples ([Figure 10F](#f10){ref-type="fig"}). Therefore, KO~2~-induced nociception depends on COX-2.

![KO~2~ induced COX-2-dependent nociception. Mice were treated with celecoxib (30 mg/kg, *ip*) or vehicle (saline) 1 h before *ipl* (30 µg, 25 µL) or *ip* (1 mg/mice) injection of KO~2~. The intensity of mechanical hyperalgesia (*A*) and thermal hyperalgesia (*B*) were measured 0.5-7 h after stimulus, paw flinching (*C*) and licking (*D*) were evaluated during 30 min, and writhing response was evaluated during 20 min (*E*). COX-2 mRNA expression (*F*) was evaluated by qPCR 0.5-7 h after *ipl* injection of KO~2~. Data are reported as means±SE. \*P\<0.05 *vs* saline control; ^\#^P\<0.05 *vs* vehicle control (0 mg/kg) (one-way ANOVA followed by Tukey\'s *t*-test).](1414-431X-bjmbr-48-04-00321-gf010){#f10}

Discussion
==========

Superoxide anion has been established as an important mediator of pain and inflammation ([@B06]-[@B09]). Most of the evidence in this regard targeted superoxide anion metabolism to evaluate its inflammatory and nociceptive effects. An important approach to study the effects of superoxide anion would be to inject a superoxide anion donor such as KO~2~. KO~2~ injection induces thermal hyperalgesia in the Hargreaves test ([@B07],[@B10]). In the present study, we provided evidence for the induction of varied nociceptive and inflammatory responses in mice by administering KO~2~. The KO~2~-induced nociceptive behaviors were responsive to treatment with the opioid receptor agonist, morphine, and COX-2 selective inhibitor, celecoxib ([@B18],[@B19]). Furthermore, an antioxidant with analgesic and anti-inflammatory effects, quercetin ([@B02],[@B04]), inhibited KO~2~-induced pain, inflammation, and oxidative stress.

KO~2~ has been used as a generator of superoxide anion *in vivo* ([@B07],[@B10]). Superoxide anion is generated in normal aerobic metabolism by one-electron transfer to molecular oxygen ([@B20]), as well as by NADPH oxidase during inflammation *in vivo* ([@B21]). Superoxide anion is a precursor of additional ROS with enhanced toxicity, including hydroxyl radical, hypochlorous acid, and singlet oxygen ([@B22]). Nevertheless, the actions of superoxide anion are not solely related to deleterious effects, but rather it is also a signaling molecule. For instance, neuropathy- and inflammation-induced superoxide anion activate p38 mitogen-activated protein (MAP) kinase, which in turn activates the transcription factor NFκB, and JNK and ERK MAP kinases, which activate activating protein-1 (AP-1). NFκB and AP-1 increase the expression of pro-inflammatory molecules ([@B01],[@B10],[@B23]).

KO~2~ injection is a simple procedure that can be reproduced in any laboratory, making it easy to access the mechanisms triggered by increased superoxide anion levels. It is essential to inject KO~2~ solution up to 5 min after its preparation, since the levels of superoxide anion decay rapidly in aqueous solution. KO~2~ induced pronounced inflammatory and nociceptive responses irrespective of the administration foci. Therefore, its action is not restricted to one tissue. This model of superoxide anion-dependent inflammation and pain exhibited dose-dependent effects, except in abdominal writhing behavior in which only the higher dose tested was capable of inducing this behavior. Moreover, the dose of KO~2~ of 100 µg/paw did not induce further increases in mechanical and thermal hyperalgesia compared to the dose of 30 µg/paw. It is possible that 100 µg/paw induced an exaggerated inflammatory response. This condition is similar to sepsis, in which there is paralysis of neutrophil recruitment when the primary infectious foci are not under control and overt inflammation and infection become systemic ([@B24]). Accordingly, 100 µg/paw of KO~2~ induced equal or even lower responses compared to 10 µg/paw with respect to MPO activity, total leukocytes, mononuclear cells, and neutrophil recruitment, while 30 µg/paw induced significant responses compared to 10 and 100 µg/paw. Considering that recruited neutrophils contribute to hyperalgesia ([@B25]-[@B27]), it is likely that reduced leukocyte recruitment with 100 µg compared to 30 µg of KO~2~ also helps explain why 100 µg did not induce further increases in nociception. Another important feature of the model is its susceptibility to pre- and post-treatment, as observed for quercetin and celecoxib, and morphine, respectively.

In addition to KO~2~ injection ([@B07],[@B10]), previous models of ROS-induced inflammation and pain include inhibitors of hyperalgesia induced by mitochondrial electron transport complexes I (rotenone) and III (antimycin) ([@B28]), administration of the ROS donor tert-butyl hydroperoxide-induced hyperalgesia ([@B29]), and peroxynitrite-induced enhancement of carrageenan-induced paw edema and thermal hyperalgesia ([@B08]). The emerging literature demonstrated that modulation of superoxide anion using SOD mimetics (M40403, TEMPOL) and peroxynitrite levels using the peroxynitrite decomposition catalyst \[FeTM-4-PyP(5+)\] reduce inflammatory mechanical hyperalgesia ([@B23]), thermal hyperalgesia ([@B07],[@B08],[@B10],[@B30]), paw flinching, paw licking ([@B31]), paw edema ([@B08],[@B10]), and leukocyte recruitment ([@B21]). To our knowledge, this is the first study to demonstrate that superoxide anion donor KO~2~ induces mechanical hyperalgesia, thermal hyperalgesia in the hot plate test, paw edema, paw licking, abdominal writhing, and neutrophil recruitment. In agreement with the role of ROS in these responses and the present data, antioxidants such as quercetin inhibit carrageenan-induced mechanical hyperalgesia, thermal hyperalgesia in the hot plate test and paw edema, formalin-induced paw licking and flinching, acetic acid- and phenyl-p-benzoquinone-induced abdominal contortions, and carrageenan-induced MPO activity in paw skin, as well as neutrophil recruitment to the abdominal cavity ([@B02],[@B05],[@B06]). These data also justify the selection of quercetin in the present study. Quercetin is able to directly scavenge superoxide anion ([@B32]), as well as inhibit COX-2 mRNA expression and prostaglandin E~2~ production ([@B33]). Therefore, this study did not exclude the possibility that quercetin could be acting by inhibiting COX-2 mRNA expression and prostaglandin E~2~ production, in addition to its antioxidant effect.

Excessive superoxide anion production has been attributed to inhibition of mitochondrial manganese SOD (MnSOD), an enzyme that controls the levels of superoxide anion. Superoxide anion reacts with nitric oxide to generate peroxynitrite that, in turn, inactivates MnSOD by nitration of Tyr-34 in a manganese-catalyzed process. This is known as a "feed-forward" mechanism that allows further accumulation of superoxide anion and peroxynitrite ([@B09]). Despite the hypothesis that peroxynitrite mediates superoxide anion-induced hyperalgesia, there is evidence that nitric oxide and superoxide anion may operate independently of each other to induce pain ([@B34]).

Intrathecal administration of tert-butyl hydroperoxide (a ROS donor) increases the frequency and amplitude of spontaneous excitatory postsynaptic currents in neurons, which was inhibited by antagonists of non-N-methyl-D-aspartate glutamate, TRPA1 and TRPV1 receptors. These results indicate a neuronal effect of ROS by inducing glutamate release and TRPA1 and TRPV1 activity ([@B29]). Thus, ROS may act as neuronal activators, which lines up well with the immediate nociceptive responses observed by injection of KO~2~, such as paw flinching, paw licking, and abdominal contortions. On the other hand, superoxide anion (from pyrogallol) and hydroxyl radical (from Fe-EDTA in hydrogen peroxide) did not induce ongoing activity or nociceptor sensitization to heat and mechanical stimuli ([@B35]), arguing against a direct neuronal effect of ROS. Considering that the effects of KO~2~ include the induction of leukocyte recruiment, which depends on activation of tissue resident cells, the present data corroborate that ROS may trigger direct and indirect neuronal events ([@B29],[@B35]).

In conclusion, the present data add to the literature regarding the inflammatory and nociceptive roles of superoxide anion and ROS, and demonstrate that KO~2~ is a useful tool to trigger a great variety of superoxide anion-dependent inflammatory and nociceptive responses, which include thermal hyperalgesia in the Hargreaves test ([@B07]), mechanical hyperalgesia, thermal hyperalgesia in the hot plate test, paw edema, paw licking, paw flinching, abdominal writhing, and neutrophil recruitment (present data).
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